| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| B7-H1 Antigen | 14 | 2022 | 1022 | 1.440 |
Why?
|
| Tumor Escape | 6 | 2021 | 251 | 0.870 |
Why?
|
| Breast Neoplasms | 31 | 2022 | 15694 | 0.560 |
Why?
|
| Receptor, ErbB-2 | 15 | 2019 | 2518 | 0.550 |
Why?
|
| Gene Expression Regulation, Neoplastic | 19 | 2021 | 8873 | 0.530 |
Why?
|
| ErbB Receptors | 9 | 2018 | 2295 | 0.500 |
Why?
|
| Triple Negative Breast Neoplasms | 5 | 2022 | 1215 | 0.410 |
Why?
|
| Cell Line, Tumor | 30 | 2022 | 14551 | 0.360 |
Why?
|
| Phosphorylation | 18 | 2019 | 4804 | 0.360 |
Why?
|
| Mice, Inbred BALB C | 15 | 2021 | 2314 | 0.360 |
Why?
|
| Ribonuclease, Pancreatic | 2 | 2021 | 53 | 0.350 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 3 | 2019 | 163 | 0.340 |
Why?
|
| Carcinogenesis | 3 | 2021 | 1026 | 0.340 |
Why?
|
| Mice | 46 | 2022 | 34495 | 0.330 |
Why?
|
| Adenovirus E1A Proteins | 6 | 2009 | 163 | 0.310 |
Why?
|
| T-Lymphocytes | 4 | 2022 | 3869 | 0.290 |
Why?
|
| Mammary Neoplasms, Experimental | 5 | 2019 | 494 | 0.290 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 2 | 2019 | 245 | 0.290 |
Why?
|
| Animals | 49 | 2022 | 59536 | 0.270 |
Why?
|
| Signal Transduction | 17 | 2019 | 11965 | 0.260 |
Why?
|
| Antibodies, Monoclonal | 5 | 2022 | 4367 | 0.260 |
Why?
|
| Mouth Neoplasms | 3 | 1999 | 713 | 0.250 |
Why?
|
| Receptors, Eph Family | 2 | 2022 | 19 | 0.250 |
Why?
|
| Proto-Oncogene Proteins c-akt | 8 | 2016 | 2054 | 0.250 |
Why?
|
| Proto-Oncogene Proteins | 7 | 2020 | 2488 | 0.250 |
Why?
|
| Immunologic Surveillance | 3 | 2018 | 60 | 0.240 |
Why?
|
| Twist-Related Protein 1 | 2 | 2016 | 127 | 0.230 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 2 | 2020 | 661 | 0.230 |
Why?
|
| Mice, Nude | 14 | 2021 | 4307 | 0.220 |
Why?
|
| Neoplasm Proteins | 5 | 2019 | 3230 | 0.220 |
Why?
|
| RNA, Long Noncoding | 2 | 2019 | 598 | 0.220 |
Why?
|
| Cell Proliferation | 10 | 2020 | 7226 | 0.220 |
Why?
|
| Neoplasms | 9 | 2022 | 15193 | 0.220 |
Why?
|
| Tumor Necrosis Factor-alpha | 4 | 2016 | 1538 | 0.210 |
Why?
|
| Programmed Cell Death 1 Receptor | 3 | 2018 | 1048 | 0.210 |
Why?
|
| Cyclin-Dependent Kinase 9 | 1 | 2022 | 64 | 0.210 |
Why?
|
| Galectins | 1 | 2022 | 71 | 0.200 |
Why?
|
| Epithelial-Mesenchymal Transition | 4 | 2018 | 973 | 0.200 |
Why?
|
| Ephrin-A4 | 1 | 2021 | 7 | 0.200 |
Why?
|
| Tumor Suppressor Protein p53 | 6 | 2019 | 3552 | 0.200 |
Why?
|
| Carcinoma, Hepatocellular | 4 | 2020 | 2027 | 0.200 |
Why?
|
| Neoplastic Stem Cells | 2 | 2021 | 1443 | 0.200 |
Why?
|
| Ribonucleases | 1 | 2020 | 88 | 0.190 |
Why?
|
| Cell Adhesion | 2 | 2013 | 1008 | 0.190 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2021 | 235 | 0.190 |
Why?
|
| Pyroptosis | 1 | 2020 | 22 | 0.190 |
Why?
|
| Receptors, Glucocorticoid | 1 | 2021 | 192 | 0.190 |
Why?
|
| NF-kappa B | 4 | 2016 | 1549 | 0.190 |
Why?
|
| Ubiquitination | 6 | 2019 | 575 | 0.180 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 3 | 2014 | 507 | 0.180 |
Why?
|
| Neoplasms, Experimental | 3 | 2019 | 750 | 0.180 |
Why?
|
| Cell Death | 1 | 2022 | 671 | 0.180 |
Why?
|
| Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase | 1 | 2019 | 21 | 0.170 |
Why?
|
| Humans | 70 | 2022 | 261506 | 0.170 |
Why?
|
| Receptor, ErbB-3 | 1 | 1999 | 122 | 0.170 |
Why?
|
| Lipoylation | 1 | 2018 | 8 | 0.170 |
Why?
|
| Protein Stability | 5 | 2019 | 370 | 0.170 |
Why?
|
| RNA, Neoplasm | 2 | 2017 | 771 | 0.170 |
Why?
|
| TNF Receptor-Associated Factor 6 | 1 | 2019 | 37 | 0.170 |
Why?
|
| Thiolester Hydrolases | 1 | 2019 | 34 | 0.170 |
Why?
|
| Repressor Proteins | 4 | 2017 | 1664 | 0.170 |
Why?
|
| Xenograft Model Antitumor Assays | 7 | 2022 | 3821 | 0.170 |
Why?
|
| Antineoplastic Agents | 9 | 2022 | 14289 | 0.170 |
Why?
|
| Protein Kinase C-delta | 1 | 2018 | 42 | 0.170 |
Why?
|
| Tumor Cells, Cultured | 15 | 2020 | 5395 | 0.170 |
Why?
|
| Acyltransferases | 1 | 2018 | 62 | 0.170 |
Why?
|
| Zinc Finger Protein GLI1 | 2 | 2016 | 111 | 0.170 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2018 | 5178 | 0.170 |
Why?
|
| Carcinoma, Pancreatic Ductal | 2 | 2021 | 1724 | 0.170 |
Why?
|
| Janus Kinase 1 | 1 | 2019 | 121 | 0.160 |
Why?
|
| Hexosyltransferases | 1 | 2018 | 10 | 0.160 |
Why?
|
| Oncogenes | 2 | 2019 | 673 | 0.160 |
Why?
|
| Transcription Activator-Like Effector Nucleases | 1 | 2018 | 6 | 0.160 |
Why?
|
| Antigen Presentation | 1 | 2019 | 272 | 0.160 |
Why?
|
| Cyclin-Dependent Kinase 2 | 1 | 2019 | 249 | 0.160 |
Why?
|
| Female | 47 | 2022 | 141928 | 0.160 |
Why?
|
| RecQ Helicases | 1 | 2018 | 102 | 0.160 |
Why?
|
| Immune Evasion | 1 | 2018 | 73 | 0.160 |
Why?
|
| Antibodies, Neutralizing | 1 | 2022 | 541 | 0.150 |
Why?
|
| Human Embryonic Stem Cells | 1 | 2018 | 33 | 0.150 |
Why?
|
| AMP-Activated Protein Kinases | 2 | 2018 | 413 | 0.150 |
Why?
|
| Specimen Handling | 1 | 2019 | 299 | 0.150 |
Why?
|
| Pancreatic Neoplasms | 3 | 2021 | 5061 | 0.150 |
Why?
|
| Transcription Factors | 4 | 2012 | 5270 | 0.150 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 2 | 2022 | 479 | 0.150 |
Why?
|
| Apoptosis | 8 | 2020 | 7591 | 0.150 |
Why?
|
| DNA Methylation | 2 | 2017 | 2669 | 0.140 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2018 | 388 | 0.140 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2018 | 203 | 0.140 |
Why?
|
| Immunohistochemistry | 7 | 2022 | 7548 | 0.140 |
Why?
|
| Liver Neoplasms | 3 | 2020 | 4557 | 0.140 |
Why?
|
| Ubiquitin-Conjugating Enzymes | 1 | 2017 | 93 | 0.140 |
Why?
|
| Poly (ADP-Ribose) Polymerase-1 | 1 | 2017 | 170 | 0.140 |
Why?
|
| Antibodies | 1 | 2019 | 838 | 0.140 |
Why?
|
| Transfection | 12 | 2016 | 2944 | 0.140 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 2 | 2018 | 992 | 0.130 |
Why?
|
| Genetic Therapy | 6 | 2011 | 1616 | 0.130 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2020 | 1756 | 0.130 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2019 | 419 | 0.130 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2020 | 4757 | 0.130 |
Why?
|
| Protein-Arginine N-Methyltransferases | 1 | 2017 | 209 | 0.130 |
Why?
|
| Gene Editing | 1 | 2018 | 216 | 0.130 |
Why?
|
| Exosomes | 1 | 2018 | 253 | 0.130 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2019 | 803 | 0.130 |
Why?
|
| I-kappa B Kinase | 3 | 2012 | 250 | 0.130 |
Why?
|
| Biomarkers, Tumor | 5 | 2020 | 10331 | 0.130 |
Why?
|
| Estrogen Receptor alpha | 1 | 2019 | 701 | 0.130 |
Why?
|
| Peptide Hydrolases | 1 | 2016 | 256 | 0.130 |
Why?
|
| Interleukin-6 | 1 | 2019 | 1038 | 0.120 |
Why?
|
| Sirtuins | 1 | 2014 | 44 | 0.120 |
Why?
|
| Metformin | 1 | 2018 | 378 | 0.120 |
Why?
|
| CTLA-4 Antigen | 1 | 2018 | 657 | 0.120 |
Why?
|
| Forkhead Transcription Factors | 1 | 2019 | 778 | 0.120 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 1999 | 5437 | 0.120 |
Why?
|
| DNA-Binding Proteins | 2 | 2020 | 4821 | 0.120 |
Why?
|
| Hypoglycemic Agents | 1 | 2018 | 586 | 0.120 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2019 | 1678 | 0.120 |
Why?
|
| Transcriptional Activation | 3 | 2018 | 1070 | 0.120 |
Why?
|
| Up-Regulation | 2 | 2018 | 2450 | 0.120 |
Why?
|
| Liver Neoplasms, Experimental | 2 | 2011 | 196 | 0.120 |
Why?
|
| Glycosylation | 3 | 2019 | 213 | 0.120 |
Why?
|
| Adenocarcinoma | 4 | 2018 | 7789 | 0.120 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2019 | 986 | 0.120 |
Why?
|
| Mammary Glands, Animal | 3 | 2010 | 533 | 0.120 |
Why?
|
| HEK293 Cells | 4 | 2021 | 1489 | 0.120 |
Why?
|
| Mediator Complex | 1 | 2013 | 69 | 0.110 |
Why?
|
| Janus Kinase 2 | 1 | 2017 | 679 | 0.110 |
Why?
|
| Cell Transformation, Neoplastic | 4 | 2019 | 2359 | 0.110 |
Why?
|
| Argonaute Proteins | 1 | 2013 | 40 | 0.110 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2016 | 1265 | 0.110 |
Why?
|
| TNF Receptor-Associated Factor 4 | 1 | 2013 | 23 | 0.110 |
Why?
|
| Glycolysis | 1 | 2016 | 519 | 0.110 |
Why?
|
| Gene Knockout Techniques | 1 | 2013 | 276 | 0.110 |
Why?
|
| Cell Hypoxia | 1 | 2013 | 328 | 0.110 |
Why?
|
| Hepatocyte Nuclear Factor 3-beta | 1 | 2011 | 40 | 0.100 |
Why?
|
| Nuclear Proteins | 3 | 2013 | 3343 | 0.100 |
Why?
|
| Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2012 | 131 | 0.100 |
Why?
|
| Breast | 3 | 2016 | 1344 | 0.100 |
Why?
|
| Cytosine Deaminase | 1 | 2011 | 39 | 0.100 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2013 | 347 | 0.100 |
Why?
|
| Cytidine Deaminase | 1 | 2011 | 83 | 0.100 |
Why?
|
| Cell Nucleus | 3 | 2018 | 1620 | 0.100 |
Why?
|
| Pentosyltransferases | 1 | 2011 | 25 | 0.100 |
Why?
|
| MCF-7 Cells | 3 | 2019 | 550 | 0.100 |
Why?
|
| Endostatins | 1 | 2011 | 48 | 0.100 |
Why?
|
| Tumor Microenvironment | 5 | 2022 | 2864 | 0.100 |
Why?
|
| Neoplasm Transplantation | 5 | 2018 | 1519 | 0.100 |
Why?
|
| Cell Survival | 4 | 2022 | 3045 | 0.090 |
Why?
|
| Protein Binding | 6 | 2021 | 3438 | 0.090 |
Why?
|
| Promoter Regions, Genetic | 5 | 2010 | 3101 | 0.090 |
Why?
|
| Trans-Activators | 3 | 2009 | 1555 | 0.090 |
Why?
|
| Receptor, Notch1 | 1 | 2011 | 218 | 0.090 |
Why?
|
| src-Family Kinases | 1 | 2013 | 478 | 0.090 |
Why?
|
| Nuclear Receptor Coactivator 3 | 1 | 2013 | 383 | 0.090 |
Why?
|
| Prognosis | 10 | 2018 | 21713 | 0.090 |
Why?
|
| Down-Regulation | 3 | 2019 | 2074 | 0.090 |
Why?
|
| MicroRNAs | 3 | 2013 | 2947 | 0.090 |
Why?
|
| RNA Helicases | 1 | 2010 | 101 | 0.090 |
Why?
|
| Neovascularization, Pathologic | 2 | 2011 | 1547 | 0.090 |
Why?
|
| Membrane Proteins | 2 | 2018 | 2819 | 0.090 |
Why?
|
| TOR Serine-Threonine Kinases | 2 | 2017 | 1546 | 0.090 |
Why?
|
| Hedgehog Proteins | 1 | 2012 | 424 | 0.090 |
Why?
|
| Stress, Physiological | 1 | 2013 | 492 | 0.090 |
Why?
|
| Cell Cycle Proteins | 2 | 2013 | 2045 | 0.090 |
Why?
|
| RNA, Messenger | 4 | 2013 | 6150 | 0.090 |
Why?
|
| Disease Progression | 5 | 2019 | 6682 | 0.090 |
Why?
|
| DNA Replication | 1 | 2013 | 744 | 0.080 |
Why?
|
| Histones | 1 | 2016 | 1466 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2008 | 1493 | 0.080 |
Why?
|
| Tyrosine | 3 | 2022 | 498 | 0.080 |
Why?
|
| Brain Neoplasms | 2 | 2017 | 4849 | 0.080 |
Why?
|
| Peptidylprolyl Isomerase | 1 | 2008 | 73 | 0.080 |
Why?
|
| Inflammatory Breast Neoplasms | 1 | 2013 | 509 | 0.080 |
Why?
|
| Mammary Glands, Human | 2 | 2019 | 184 | 0.080 |
Why?
|
| Hepatitis B virus | 1 | 2009 | 217 | 0.080 |
Why?
|
| Epidermal Growth Factor | 2 | 2016 | 423 | 0.080 |
Why?
|
| Histone Deacetylases | 1 | 2009 | 365 | 0.080 |
Why?
|
| Benzenesulfonates | 1 | 2008 | 195 | 0.080 |
Why?
|
| Antineoplastic Agents, Phytogenic | 2 | 2004 | 852 | 0.080 |
Why?
|
| Neoplasm Metastasis | 2 | 2017 | 5112 | 0.070 |
Why?
|
| HeLa Cells | 3 | 2018 | 1643 | 0.070 |
Why?
|
| Genes, p53 | 1 | 2011 | 1090 | 0.070 |
Why?
|
| beta-Transducin Repeat-Containing Proteins | 2 | 2016 | 40 | 0.070 |
Why?
|
| Cell Division | 5 | 2004 | 2489 | 0.070 |
Why?
|
| MAP Kinase Signaling System | 2 | 2008 | 848 | 0.070 |
Why?
|
| Telomerase | 1 | 2009 | 525 | 0.070 |
Why?
|
| Ovarian Neoplasms | 4 | 2009 | 4638 | 0.070 |
Why?
|
| Epithelial Cells | 3 | 2018 | 1818 | 0.070 |
Why?
|
| Mice, Inbred NOD | 2 | 2018 | 905 | 0.070 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2021 | 3639 | 0.070 |
Why?
|
| Head and Neck Neoplasms | 2 | 1999 | 3976 | 0.070 |
Why?
|
| Mice, Transgenic | 4 | 2019 | 4143 | 0.060 |
Why?
|
| Paclitaxel | 2 | 2004 | 1996 | 0.060 |
Why?
|
| Gene Expression Profiling | 4 | 2020 | 5159 | 0.060 |
Why?
|
| Gene Knockdown Techniques | 2 | 2021 | 1077 | 0.060 |
Why?
|
| Mice, Knockout | 3 | 2019 | 5710 | 0.060 |
Why?
|
| Cell Line | 5 | 2021 | 5114 | 0.060 |
Why?
|
| Enzyme Inhibitors | 3 | 2001 | 1879 | 0.060 |
Why?
|
| In Situ Hybridization | 1 | 2006 | 1037 | 0.060 |
Why?
|
| Stem Cells | 1 | 2011 | 1213 | 0.060 |
Why?
|
| Benzamides | 2 | 2019 | 1832 | 0.060 |
Why?
|
| Cyclin D1 | 2 | 2010 | 576 | 0.060 |
Why?
|
| Melanoma | 1 | 2020 | 5317 | 0.060 |
Why?
|
| Cell Movement | 3 | 2016 | 2466 | 0.060 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2014 | 3251 | 0.060 |
Why?
|
| Immunotherapy | 3 | 2022 | 3341 | 0.060 |
Why?
|
| Positive Transcriptional Elongation Factor B | 1 | 2022 | 35 | 0.050 |
Why?
|
| Antisense Elements (Genetics) | 1 | 2001 | 18 | 0.050 |
Why?
|
| Iron-Sulfur Proteins | 1 | 2001 | 22 | 0.050 |
Why?
|
| Disease Models, Animal | 4 | 2022 | 7222 | 0.050 |
Why?
|
| Genetic Vectors | 5 | 2011 | 1694 | 0.050 |
Why?
|
| DNA | 1 | 2010 | 2693 | 0.050 |
Why?
|
| Blotting, Western | 3 | 2013 | 3536 | 0.050 |
Why?
|
| Anoikis | 1 | 2001 | 63 | 0.050 |
Why?
|
| Gene Transfer, Horizontal | 1 | 2001 | 57 | 0.050 |
Why?
|
| Ubiquitins | 1 | 2001 | 86 | 0.050 |
Why?
|
| AC133 Antigen | 1 | 2021 | 110 | 0.050 |
Why?
|
| Pyridines | 1 | 2008 | 1244 | 0.050 |
Why?
|
| Adaptor Proteins, Vesicular Transport | 1 | 2001 | 94 | 0.050 |
Why?
|
| Mice, Inbred A | 1 | 2020 | 33 | 0.050 |
Why?
|
| Antineoplastic Agents, Immunological | 2 | 2022 | 1249 | 0.050 |
Why?
|
| CD146 Antigen | 1 | 2020 | 57 | 0.050 |
Why?
|
| Cell Migration Assays | 1 | 2020 | 11 | 0.050 |
Why?
|
| Survival Analysis | 3 | 2013 | 9180 | 0.050 |
Why?
|
| Lactation Disorders | 1 | 2000 | 8 | 0.050 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2022 | 324 | 0.050 |
Why?
|
| Predictive Value of Tests | 2 | 2019 | 4892 | 0.050 |
Why?
|
| 3T3 Cells | 4 | 2001 | 355 | 0.050 |
Why?
|
| Growth Inhibitors | 1 | 2000 | 149 | 0.050 |
Why?
|
| Receptor, ErbB-4 | 1 | 1999 | 23 | 0.050 |
Why?
|
| Immunoblotting | 1 | 2021 | 886 | 0.050 |
Why?
|
| Models, Statistical | 1 | 2006 | 1171 | 0.050 |
Why?
|
| Indolizines | 1 | 2019 | 45 | 0.050 |
Why?
|
| Brain | 1 | 2013 | 4113 | 0.040 |
Why?
|
| Adult | 9 | 2018 | 77950 | 0.040 |
Why?
|
| Genes, Tumor Suppressor | 2 | 2001 | 1064 | 0.040 |
Why?
|
| Male | 10 | 2020 | 123000 | 0.040 |
Why?
|
| Pyridinium Compounds | 1 | 2019 | 63 | 0.040 |
Why?
|
| Middle Aged | 9 | 2021 | 86204 | 0.040 |
Why?
|
| THP-1 Cells | 1 | 2019 | 55 | 0.040 |
Why?
|
| Cyclic N-Oxides | 1 | 2019 | 106 | 0.040 |
Why?
|
| Emodin | 1 | 1999 | 14 | 0.040 |
Why?
|
| A549 Cells | 1 | 2019 | 124 | 0.040 |
Why?
|
| Cyclins | 1 | 2001 | 456 | 0.040 |
Why?
|
| Palmitates | 1 | 2018 | 23 | 0.040 |
Why?
|
| rho GTP-Binding Proteins | 1 | 2000 | 177 | 0.040 |
Why?
|
| Random Allocation | 1 | 2020 | 703 | 0.040 |
Why?
|
| False Negative Reactions | 1 | 2019 | 275 | 0.040 |
Why?
|
| Transplantation, Heterologous | 3 | 2011 | 1082 | 0.040 |
Why?
|
| Granzymes | 1 | 2019 | 91 | 0.040 |
Why?
|
| Necrosis | 1 | 2020 | 580 | 0.040 |
Why?
|
| Jurkat Cells | 1 | 2019 | 311 | 0.040 |
Why?
|
| Biomarkers | 2 | 2022 | 5047 | 0.040 |
Why?
|
| Antibody Specificity | 1 | 2019 | 334 | 0.040 |
Why?
|
| Benzylidene Compounds | 1 | 2018 | 9 | 0.040 |
Why?
|
| Genes, Viral | 1 | 1999 | 202 | 0.040 |
Why?
|
| Pyrrolidinones | 1 | 2019 | 61 | 0.040 |
Why?
|
| Cytoplasm | 1 | 2001 | 652 | 0.040 |
Why?
|
| Inflammasomes | 1 | 2020 | 161 | 0.040 |
Why?
|
| Endoplasmic Reticulum-Associated Degradation | 1 | 2018 | 35 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 2 | 2021 | 6942 | 0.040 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2019 | 234 | 0.040 |
Why?
|
| Biphenyl Compounds | 1 | 2019 | 194 | 0.040 |
Why?
|
| Aged | 8 | 2018 | 70117 | 0.040 |
Why?
|
| Esophageal Neoplasms | 1 | 2012 | 3168 | 0.040 |
Why?
|
| Autocrine Communication | 1 | 2018 | 84 | 0.040 |
Why?
|
| Triazines | 1 | 2019 | 117 | 0.040 |
Why?
|
| Morpholines | 1 | 2019 | 289 | 0.040 |
Why?
|
| N-Acetylglucosaminyltransferases | 1 | 2018 | 46 | 0.040 |
Why?
|
| Poly-ADP-Ribose Binding Proteins | 1 | 2018 | 109 | 0.040 |
Why?
|
| DNA Topoisomerases, Type II | 1 | 2018 | 116 | 0.040 |
Why?
|
| Mutation | 4 | 2018 | 15179 | 0.040 |
Why?
|
| Ligands | 1 | 2020 | 995 | 0.040 |
Why?
|
| Cell Membrane | 1 | 2001 | 850 | 0.040 |
Why?
|
| beta Catenin | 2 | 2018 | 688 | 0.040 |
Why?
|
| Cytoskeletal Proteins | 1 | 2000 | 492 | 0.040 |
Why?
|
| U937 Cells | 1 | 2017 | 171 | 0.040 |
Why?
|
| Hypoxia | 1 | 2020 | 443 | 0.040 |
Why?
|
| Binding Sites | 2 | 2018 | 2171 | 0.040 |
Why?
|
| Paracrine Communication | 1 | 2018 | 128 | 0.040 |
Why?
|
| In Situ Nick-End Labeling | 3 | 2004 | 448 | 0.040 |
Why?
|
| NIH 3T3 Cells | 1 | 2017 | 260 | 0.040 |
Why?
|
| Receptors, Progesterone | 2 | 2019 | 1392 | 0.040 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 1 | 2017 | 164 | 0.040 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2022 | 854 | 0.040 |
Why?
|
| Pyridones | 1 | 2019 | 348 | 0.040 |
Why?
|
| Recombinant Proteins | 5 | 2001 | 2927 | 0.040 |
Why?
|
| Aniline Compounds | 1 | 2018 | 177 | 0.040 |
Why?
|
| Serine | 1 | 2018 | 388 | 0.040 |
Why?
|
| COP9 Signalosome Complex | 1 | 2016 | 72 | 0.040 |
Why?
|
| Gene Expression Regulation | 3 | 2010 | 4053 | 0.040 |
Why?
|
| Endoplasmic Reticulum | 1 | 2018 | 308 | 0.040 |
Why?
|
| Cattle | 1 | 2018 | 783 | 0.040 |
Why?
|
| Microscopy, Confocal | 1 | 2018 | 663 | 0.040 |
Why?
|
| Aerobiosis | 1 | 2016 | 30 | 0.030 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2001 | 1823 | 0.030 |
Why?
|
| Catalysis | 1 | 2016 | 250 | 0.030 |
Why?
|
| Cytosol | 1 | 2016 | 238 | 0.030 |
Why?
|
| Colorectal Neoplasms | 1 | 2011 | 3578 | 0.030 |
Why?
|
| Pyruvate Kinase | 1 | 2016 | 36 | 0.030 |
Why?
|
| Curcumin | 1 | 2016 | 117 | 0.030 |
Why?
|
| Melanoma, Experimental | 1 | 2018 | 368 | 0.030 |
Why?
|
| RNA-Binding Proteins | 1 | 2001 | 984 | 0.030 |
Why?
|
| Heterografts | 1 | 2018 | 733 | 0.030 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2019 | 488 | 0.030 |
Why?
|
| Homozygote | 1 | 2018 | 717 | 0.030 |
Why?
|
| Clinical Decision-Making | 1 | 2019 | 524 | 0.030 |
Why?
|
| Quinolines | 1 | 2019 | 383 | 0.030 |
Why?
|
| Cetuximab | 1 | 2017 | 472 | 0.030 |
Why?
|
| Stilbenes | 1 | 2016 | 86 | 0.030 |
Why?
|
| Heterozygote | 1 | 2018 | 1020 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 2 | 2013 | 3981 | 0.030 |
Why?
|
| Methylation | 1 | 2016 | 597 | 0.030 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2016 | 146 | 0.030 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2017 | 376 | 0.030 |
Why?
|
| Aged, 80 and over | 3 | 2018 | 29902 | 0.030 |
Why?
|
| Base Sequence | 3 | 2011 | 4917 | 0.030 |
Why?
|
| Antigens, Neoplasm | 2 | 2017 | 1506 | 0.030 |
Why?
|
| RNA Interference | 1 | 2018 | 1408 | 0.030 |
Why?
|
| Adenoma | 1 | 2019 | 716 | 0.030 |
Why?
|
| Microscopy, Fluorescence | 2 | 2011 | 769 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2018 | 1869 | 0.030 |
Why?
|
| Genetic Markers | 1 | 1997 | 974 | 0.030 |
Why?
|
| Proteolysis | 1 | 2016 | 370 | 0.030 |
Why?
|
| Cells, Cultured | 2 | 2019 | 5637 | 0.030 |
Why?
|
| Minichromosome Maintenance Complex Component 7 | 1 | 2013 | 14 | 0.030 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 1 | 2019 | 923 | 0.030 |
Why?
|
| Phosphotyrosine | 1 | 2013 | 111 | 0.030 |
Why?
|
| Ubiquitin-Specific Peptidase 7 | 1 | 2013 | 40 | 0.030 |
Why?
|
| Proteins | 1 | 2001 | 1963 | 0.030 |
Why?
|
| Imidazoles | 1 | 2019 | 999 | 0.030 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2018 | 1016 | 0.030 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2013 | 153 | 0.030 |
Why?
|
| Integrin beta1 | 1 | 2013 | 126 | 0.030 |
Why?
|
| Models, Biological | 2 | 2012 | 3254 | 0.030 |
Why?
|
| Ubiquitin-Specific Proteases | 1 | 2013 | 73 | 0.030 |
Why?
|
| Focal Adhesion Protein-Tyrosine Kinases | 1 | 2013 | 161 | 0.030 |
Why?
|
| RNA Precursors | 1 | 2013 | 137 | 0.030 |
Why?
|
| Nucleic Acid Conformation | 1 | 2013 | 279 | 0.030 |
Why?
|
| Protein Biosynthesis | 2 | 2009 | 889 | 0.030 |
Why?
|
| Cytoskeleton | 1 | 2013 | 267 | 0.030 |
Why?
|
| APOBEC-3G Deaminase | 1 | 2011 | 6 | 0.030 |
Why?
|
| Ribonuclease III | 1 | 2013 | 182 | 0.030 |
Why?
|
| Immunoprecipitation | 1 | 2013 | 591 | 0.030 |
Why?
|
| Macrophages | 1 | 2018 | 1304 | 0.030 |
Why?
|
| Reproducibility of Results | 2 | 2019 | 6009 | 0.030 |
Why?
|
| Consensus Sequence | 2 | 2001 | 117 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2021 | 6207 | 0.030 |
Why?
|
| Trastuzumab | 1 | 2014 | 696 | 0.030 |
Why?
|
| Endopeptidases | 1 | 2013 | 220 | 0.030 |
Why?
|
| Patient Selection | 1 | 2019 | 2055 | 0.030 |
Why?
|
| Entosis | 1 | 2011 | 4 | 0.030 |
Why?
|
| Quinazolines | 1 | 2016 | 923 | 0.030 |
Why?
|
| Lymphocyte Activation | 1 | 2016 | 1688 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2013 | 1062 | 0.020 |
Why?
|
| Cytokinesis | 1 | 2011 | 57 | 0.020 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2011 | 256 | 0.020 |
Why?
|
| Combined Modality Therapy | 2 | 2004 | 8865 | 0.020 |
Why?
|
| Histone Deacetylase 2 | 1 | 2009 | 35 | 0.020 |
Why?
|
| Viral Regulatory and Accessory Proteins | 1 | 2009 | 64 | 0.020 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2012 | 460 | 0.020 |
Why?
|
| Lymph Nodes | 1 | 1980 | 2967 | 0.020 |
Why?
|
| Prodrugs | 1 | 2011 | 217 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2013 | 1217 | 0.020 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2010 | 323 | 0.020 |
Why?
|
| Aneuploidy | 1 | 2011 | 369 | 0.020 |
Why?
|
| NFATC Transcription Factors | 1 | 2009 | 96 | 0.020 |
Why?
|
| Treatment Outcome | 2 | 2021 | 32848 | 0.020 |
Why?
|
| Transcription Factor RelA | 1 | 2009 | 184 | 0.020 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2009 | 194 | 0.020 |
Why?
|
| Sp1 Transcription Factor | 1 | 2009 | 188 | 0.020 |
Why?
|
| Protein Transport | 2 | 2001 | 734 | 0.020 |
Why?
|
| NIMA-Interacting Peptidylprolyl Isomerase | 1 | 2008 | 60 | 0.020 |
Why?
|
| Gene Expression | 3 | 2001 | 3570 | 0.020 |
Why?
|
| DNA Primers | 2 | 2001 | 1399 | 0.020 |
Why?
|
| Mitosis | 1 | 2011 | 615 | 0.020 |
Why?
|
| Molecular Targeted Therapy | 1 | 2018 | 2330 | 0.020 |
Why?
|
| Cell Lineage | 1 | 2011 | 668 | 0.020 |
Why?
|
| beta-Galactosidase | 2 | 1999 | 211 | 0.020 |
Why?
|
| Adolescent | 2 | 1999 | 31252 | 0.020 |
Why?
|
| Cell Cycle | 1 | 2013 | 2084 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2013 | 2216 | 0.020 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2008 | 611 | 0.020 |
Why?
|
| Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2008 | 275 | 0.020 |
Why?
|
| Transcription, Genetic | 2 | 2009 | 3154 | 0.020 |
Why?
|
| Niacinamide | 1 | 2008 | 421 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2011 | 1555 | 0.020 |
Why?
|
| Genes, Reporter | 2 | 1999 | 798 | 0.020 |
Why?
|
| United States | 1 | 2022 | 15433 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2009 | 810 | 0.020 |
Why?
|
| Phenylurea Compounds | 1 | 2008 | 580 | 0.020 |
Why?
|
| Nerve Tissue Proteins | 1 | 2011 | 1491 | 0.010 |
Why?
|
| Carrier Proteins | 1 | 2012 | 2022 | 0.010 |
Why?
|
| Receptors, Estrogen | 2 | 2001 | 2086 | 0.010 |
Why?
|
| Adenoviridae | 2 | 2001 | 1459 | 0.010 |
Why?
|
| Rats | 1 | 2012 | 6086 | 0.010 |
Why?
|
| Lung Neoplasms | 2 | 2018 | 11538 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2019 | 7702 | 0.010 |
Why?
|
| Iron-Regulatory Proteins | 1 | 2001 | 11 | 0.010 |
Why?
|
| Molecular Sequence Data | 2 | 2001 | 6089 | 0.010 |
Why?
|
| Nucleic Acid Synthesis Inhibitors | 1 | 2001 | 43 | 0.010 |
Why?
|
| Inflammation | 1 | 2012 | 2522 | 0.010 |
Why?
|
| Tumor Suppressor Protein p14ARF | 1 | 2001 | 97 | 0.010 |
Why?
|
| Peritoneal Cavity | 1 | 2001 | 56 | 0.010 |
Why?
|
| Gene Transfer Techniques | 1 | 2004 | 716 | 0.010 |
Why?
|
| E1A-Associated p300 Protein | 1 | 2001 | 92 | 0.010 |
Why?
|
| Cell Fractionation | 1 | 2001 | 68 | 0.010 |
Why?
|
| Cell Line, Transformed | 1 | 2001 | 394 | 0.010 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2001 | 367 | 0.010 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2018 | 5319 | 0.010 |
Why?
|
| Injections | 1 | 2001 | 285 | 0.010 |
Why?
|
| Gene Targeting | 1 | 2001 | 292 | 0.010 |
Why?
|
| Genes, erbB-2 | 1 | 2001 | 229 | 0.010 |
Why?
|
| Thymidine | 1 | 2000 | 155 | 0.010 |
Why?
|
| Prolactin | 1 | 2000 | 155 | 0.010 |
Why?
|
| Amino Acid Motifs | 1 | 2001 | 392 | 0.010 |
Why?
|
| Mice, Inbred ICR | 1 | 2000 | 239 | 0.010 |
Why?
|
| Thorax | 1 | 2001 | 213 | 0.010 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2001 | 287 | 0.010 |
Why?
|
| Growth Hormone | 1 | 2000 | 226 | 0.010 |
Why?
|
| Young Adult | 1 | 2018 | 21445 | 0.010 |
Why?
|
| Etoposide | 1 | 2001 | 870 | 0.010 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2001 | 528 | 0.010 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2001 | 476 | 0.010 |
Why?
|
| Ki-67 Antigen | 1 | 2001 | 666 | 0.010 |
Why?
|
| Liposomes | 1 | 2001 | 684 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 2001 | 1618 | 0.010 |
Why?
|
| Postpartum Period | 1 | 2000 | 259 | 0.010 |
Why?
|
| Survival Rate | 2 | 2004 | 12221 | 0.010 |
Why?
|
| Coculture Techniques | 1 | 2000 | 626 | 0.010 |
Why?
|
| Immunity, Cellular | 1 | 1980 | 419 | 0.010 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2001 | 621 | 0.010 |
Why?
|
| Iron | 1 | 2001 | 376 | 0.010 |
Why?
|
| Drug Resistance | 1 | 2000 | 587 | 0.010 |
Why?
|
| Kinetics | 1 | 2001 | 2049 | 0.010 |
Why?
|
| Cholesterol | 1 | 2001 | 658 | 0.010 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2001 | 534 | 0.010 |
Why?
|
| Progesterone | 1 | 2000 | 513 | 0.010 |
Why?
|
| Pregnancy | 2 | 2001 | 7573 | 0.010 |
Why?
|
| Cytomegalovirus | 1 | 2000 | 482 | 0.010 |
Why?
|
| Carcinoma in Situ | 1 | 2001 | 487 | 0.010 |
Why?
|
| Estradiol | 1 | 2000 | 748 | 0.010 |
Why?
|
| Cross Reactions | 1 | 1997 | 266 | 0.010 |
Why?
|
| Uterus | 1 | 2001 | 678 | 0.010 |
Why?
|
| Adenoviruses, Human | 1 | 1997 | 181 | 0.010 |
Why?
|
| Ovary | 1 | 2000 | 668 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 2000 | 1764 | 0.010 |
Why?
|
| Chromatin | 1 | 2001 | 942 | 0.010 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 1999 | 604 | 0.010 |
Why?
|
| Body Weight | 1 | 2000 | 1293 | 0.010 |
Why?
|
| Sequence Alignment | 1 | 1997 | 844 | 0.010 |
Why?
|
| Drug Synergism | 1 | 1999 | 1313 | 0.010 |
Why?
|
| Child | 1 | 1997 | 29154 | 0.010 |
Why?
|
| Epitopes | 1 | 1997 | 685 | 0.010 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2001 | 1439 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 1997 | 1489 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 1997 | 37905 | 0.010 |
Why?
|
| Fibroblasts | 1 | 2001 | 1682 | 0.010 |
Why?
|
| DNA Damage | 1 | 2001 | 1954 | 0.010 |
Why?
|
| Cytokines | 1 | 2001 | 2809 | 0.010 |
Why?
|
| Adipose Tissue | 1 | 1997 | 769 | 0.010 |
Why?
|
| Virus Replication | 1 | 1995 | 709 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 1997 | 4233 | 0.010 |
Why?
|
| Lymphatic Metastasis | 1 | 1980 | 4844 | 0.010 |
Why?
|
| Carcinoma | 1 | 2001 | 2578 | 0.010 |
Why?
|
| Phenotype | 1 | 2000 | 6295 | 0.010 |
Why?
|
| Time Factors | 1 | 2000 | 12926 | 0.000 |
Why?
|